This site is intended for health professionals only

Flu vaccine results bolster hopes for combating pandemic

7 January 2008

Share this article

A vaccine that could overcome the need for annual flu booster jabs has shown promising results in a Phase 1 clinical trial.

Experts from Acambis plc say the vaccine could present a potential tool in the fight against a flu pandemic.

“We are very excited about these new data and believe that this highly innovative vaccine could be very attractive in such a competitive field,” said Ian Garland, Acambis Chief Executive Officer.

The vaccine, ACAM-FLU-A, is a recombinant vaccine linked to a Hepatitis B core protein that targets the M2e conserved region of all influenza “A” strains.

This is a sponsored advert: Please read the information below
Cogora InRead Image
Access one of the biggest primary healthcare communities across the UK
This is a sponsored advert: Please read the information above

Phase 1 clinical trials show that ACAM-FLU-A is well tolerated and immunogenic.

Michael Watson, Acambis’ executive vice president added: “M2e is one of the most discussed new approaches for influenza vaccination.

“We believe that these results confirm we have an approach worthy of further development.”


Want news like this straight to your inbox?